Senescence is a double-edged sword in cancer therapy, capable of driving tumor-promoting and tumor-suppressive responses. In this issue of Nature Aging, González-Gualda, Reinius and colleagues identify activation of TGFβ signaling as the key protumorigenic activity and a viable therapeutic target within the senescence program triggered by platinum-based chemotherapy in ovarian and lung cancers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Fleury, H. et al. Nat. Commun. 10, 2556 (2019).
Ruscetti, M. et al. Science 362, 1416–1422 (2018).
González-Gualda, E. et al. Nat. Aging https://doi.org/10.1038/s43587-025-01054-2 (2025).
Watson, S. S. et al. Cell Syst. 6, 329–342 (2018).
Al Shboul, S. et al. Sci. Rep. 13, 15903 (2023).
Domen, A. et al. Transl. Lung Cancer Res. 11, 1526–1539 (2022).
Zhang, D. et al. Mol. Cancer 23, 70 (2024).
Magkouta, S. et al. Mol. Cell 83, 3558–3573 (2023).
Schiller, J. H. et al. N. Engl. J. Med. 346, 92–98 (2002).
Vasey, P. A. et al. J. Natl. Cancer Inst. 96, 1682–1691 (2004).
Bajtai, E. et al. Mol. Cancer 24, 128 (2025).
Mukherjee, G. et al. ACS Pharmacol. Transl. Sci. 8, 4001–4016 (2025).
Coppé, J. P. et al. J. Biol. Chem. 286, 36396–36403 (2011).
Yin, Y. et al. Clin. Exp. Pharmacol. Physiol. 50, 140–148 (2023).
Matsuda, S. et al. Cell Rep. 42, 112129 (2023).
Acknowledgements
S.H. is supported by the Scotiabank Chair in the diagnosis and treatment of breast cancer, Université de Montréal. G.F. is supported by the CIBC chair for breast cancer research, Université de Montréal and the Terry Fox Research Institute.
Author information
Authors and Affiliations
Contributions
Both authors wrote the paper and undertook revisions. G.F. made the original version of Fig. 1.
Corresponding author
Ethics declarations
Competing interests
S.H. received speaker bureau fees from AstraZeneca-Merck and research funding from Exact Sciences and Pfizer. G.F. declares no competing interests.
Rights and permissions
About this article
Cite this article
Hassan, S., Ferbeyre, G. Precision targeting of the SASP in cancer therapy. Nat Aging (2026). https://doi.org/10.1038/s43587-025-01052-4
Published:
Version of record:
DOI: https://doi.org/10.1038/s43587-025-01052-4
